Akers Biosciences reported this week that its first quarter revenues dropped 55 percent year over year, as lower yields in the process of extracting antigens for its flagship test product led to lower production levels and backorders.
The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.